Key Takeaways OMER secured FDA approval for YARTEMLEA to treat TA-TMA in adults and pediatric patients aged two and older.OMER showed strong results, with complete responses up to 68% and improved 100-day survival in studies.OMER's first commercial product is set to generate revenues, with U.S. delivery planned for January 2026.Omeros Corporation (OMER) recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy ...